About VITARNA

For the first time, a community is coming together to fund and steer innovative research for a single treatment addressing multiple aspects of aging.

Artan Bio is exploring the promising field of gene therapies that could help address aging-related genetic factors. The company’s approach aims to develop therapeutic candidates that could potentially suppress mutations that drive aging.

Artan Bio is led by two entrepreneurs who have previously advanced drug development platforms into human clinical trials. 

By decentralizing funding and intellectual property ownership, this initiative gives the VitaDAO community a voice in advancing the research. Members will be able to vote on the governance of the IP, provide input on research priorities, and have a say in how funds are allocated.

It's very early-stage research, but this community-driven model opens up an exciting path for democratizing access to cutting-edge therapies. All research must undergo extensive testing in pre-clinical and clinical studies to evaluate safety and efficacy before any treatments could become available.

The goal is to pave the way for more transparent, inclusive, and equitable medical innovation.

By pooling resources and brainpower, we can work towards breakthrough solutions that could one day result in longevity for all.

The VITARNA Story

VitaDAO’s initial support for Artan Bio, via a Sponsored Research Agreement (SRA), has been to fund the design and validation of their engineered suppressor system (VDP-103) in cells with targetable mutations to confirm validity of the approach.

Artan Bio seeks to continue development of the engineered suppressor system beyond the initial project with VitaDAO to further the IP development, and further validate the system in animal models to support preclinical translation and establish a development candidate for use in clinical trials.

May 2023

The Artan Bio funding application is submitted

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

July 2023

Funding for Artan Bio via IP-NFT successfully approved by $VITA token holders

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

January 2024

VitaDAO token holders vote to Tokenize the Artan Bio IP-NFT

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

May 2024

The VITARNA IPT is developed, public sale is announced

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

June 2024

Funding Secured!
VitaDAO has successfully tokenized the IP-NFT, Artan Bio, and raised $300K

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

Claim your $VITARNA here
July 2024

VitaRNA by ArtanBIO - Data Drop

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

VITARNA Tokenomics

IP Tokens represent membership in an IP pool containing the IP and R&D data attached to their parent IP-NFT.  

The IP Tokens of the Artan Bio IP-NFT are denoted by the token symbol “VITARNA.”  

The rights of VITARNA token holders are governed by the IPT Membership Agreement.

Roadmap

Artan Bio is finalizing the experimental system to screen the variants. This system will allow us to determine the effectiveness of the various design alterations and select candidates with the desired characteristics. This will be performed in collaboration with a leading CRO.

Once completed, VitaDAO will work with Artan Bio and Dr. Torres to validate the lead constructs in animal models that would serve as the preclinical data to support further development and lead candidate selection. Once positive data has been achieved in the appropriate animal models, Artan Bio will work with CDMOs on scalability and manufacturing to support IND-enabling studies. From there, clinical studies would commence.

About the IPT crowdsale

The VitaDAO community has offered an opportunity to further support the work of Artan Bio through participation in the crowdsale of IP Tokens raising $300,000 USD in support of the project.



The genesis VITARNA token sale will be a fixed-price sale with pro rata distribution, overflow refunds, and 12 month vesting.

20% of VITARNA tokens will be sold to VITA holders at a fixed price determined by an estimated budget of the future funding needs of the project for its next phase as described below. The funds will be raised in wrapped ether (WETH) to minimise the impact of USD(C) inflation and minimise the number of swaps required by participants.

Want to directly influence outcomes in longevity science research?